亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials

塞库金单抗 医学 化脓性汗腺炎 皮肤病科 内科学 日出 银屑病 疾病 银屑病性关节炎 大气科学 地质学
作者
Christos C. Zouboulis,Thierry Passeron,David M. Pariser,Magdalena B. Wozniak,Xianjun Li,Lorenz Uhlmann,Iryna Lobach,Angela Llobet Martinez,Shoba Ravichandran,Ivette Alarcón,Annamaria Offidani,Maryam Shayesteh Alam,Pedro Mendes‐Bastos
出处
期刊:British Journal of Dermatology [Wiley]
卷期号:190 (6): 836-845 被引量:1
标识
DOI:10.1093/bjd/ljae098
摘要

Lay Summary Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful boils. HS is common and affects about 0.4% of the world’s population. Treating the condition is difficult, but drugs called ‘biologics’ can help to improve the symptoms. For example, secukinumab is a biologic drug that has been shown to be effective and well-tolerated for the treatment of HS. In this analysis, we investigated whether previous treatment with biologics could affect the effectiveness and tolerability of secukinumab. This analysis included data from two identical clinical trials (called SUNSHINE and SUNRISE) that recruited adult patients with HS who had moderate-to-severe disease. In these trials, patients took secukinumab 300 mg every 2 weeks or every 4 weeks for 1 year, or a placebo for 4 months and then switched to secukinumab until 1 year. At regular intervals, the effectiveness and tolerability of secukinumab were examined and the results were compared between patients who had previously used another biologic and patients who had never used a biologic before. After 16 weeks, patients who took secukinumab had better results than the patients who took a placebo, independent of previous biologic use. Secukinumab was still effective and had improved results over 1 year of treatment in both subgroups. Regardless of whether patients had previously been taking another biologic, secukinumab was just as tolerable as placebo and there were no new safety risks. Our analysis shows that secukinumab is effective and tolerable, regardless of whether patients have previously used another biologic drug.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
13秒前
23秒前
英俊的铭应助liu采纳,获得10
30秒前
joanna完成签到,获得积分10
35秒前
飞_完成签到,获得积分10
41秒前
42秒前
43秒前
飞_发布了新的文献求助10
45秒前
科研通AI2S应助cao采纳,获得10
1分钟前
1分钟前
1分钟前
liu发布了新的文献求助10
1分钟前
jyy应助科研通管家采纳,获得10
1分钟前
子爵木完成签到 ,获得积分10
1分钟前
科研小刘发布了新的文献求助10
2分钟前
2分钟前
chi完成签到 ,获得积分10
2分钟前
大个应助科研小刘采纳,获得10
2分钟前
迷你的靖雁完成签到,获得积分10
2分钟前
乐乐完成签到,获得积分10
3分钟前
3分钟前
淡然平蓝发布了新的文献求助10
3分钟前
3分钟前
3分钟前
天才小熊猫完成签到,获得积分10
3分钟前
jiangchuansm发布了新的文献求助20
3分钟前
3分钟前
科研小刘发布了新的文献求助10
3分钟前
linuo完成签到,获得积分10
3分钟前
orixero应助Aira采纳,获得10
3分钟前
4分钟前
xiekunwhy完成签到,获得积分10
4分钟前
夜阑听雨完成签到,获得积分0
4分钟前
容若发布了新的文献求助10
4分钟前
远方发布了新的文献求助10
4分钟前
5分钟前
科研小刘发布了新的文献求助10
5分钟前
lingduyu发布了新的文献求助10
5分钟前
5分钟前
5分钟前
高分求助中
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
宽禁带半导体紫外光电探测器 388
Case Research: The Case Writing Process 300
Global Geological Record of Lake Basins 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3142675
求助须知:如何正确求助?哪些是违规求助? 2793563
关于积分的说明 7806945
捐赠科研通 2449831
什么是DOI,文献DOI怎么找? 1303518
科研通“疑难数据库(出版商)”最低求助积分说明 626959
版权声明 601314